ホーム>>Signaling Pathways>> Obesity, Appetite Control & Diabetes>> Diabetes>>AMP-Deoxynojirimycin

AMP-Deoxynojirimycin (Synonyms: AdamantanepentyldNM, AMP-DNJ, AMPdNM, N(5adamantane1ylmethoxypentyl)Deoxynojirimycin)

カタログ番号GC41406

脂質メッセンジャーであるセラミドは、グルコシルセラミド合成酵素(GCS)によってグルコシルセラミドに変換されます。

Products are for research use only. Not for human use. We do not sell to patients.

AMP-Deoxynojirimycin 化学構造

Cas No.: 216758-20-2

サイズ 価格 在庫数 個数
500μg
$58.00
在庫あり
1mg
$111.00
在庫あり
5mg
$466.00
在庫あり
10mg
$816.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

The lipid messenger ceramide is converted to glucosylceramide by glucosylceramide synthase (GCS). In the reverse direction, non-lysosomal glucosylceramidase (GCase), also known as β-glucosidase 2 (BGD), cleaves the glucosyl moiety from glucosylceramide, liberating ceramide, which can be converted into sphingomyelin. AMP-deoxynojirimycin (AMP-dNM) is a hydrophobic derivative of dNM. It potently inhibits BGD (IC50 = 0.3 nM), less potently antagonizes GCS (IC50 = 25 nM), but only poorly inhibits other GCase isoforms. AMP-dNM has been shown to strongly suppress inflammation in a murine model of hapten-induced colitis, enhance insulin sensitivity in murine and rat models of insulin resistance, and induce sterol regulatory element-binding protein-regulated gene expression and cholesterol synthesis in HepG2 cells.

レビュー

Review for AMP-Deoxynojirimycin

Average Rating: 5 ★★★★★ (Based on Reviews and 28 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for AMP-Deoxynojirimycin

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.